A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion

Size: px
Start display at page:

Download "A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion"

Transcription

1 european urology 52 (2007) available at journal homepage: Review Kidney Cancer A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion Ziya Kirkali a, *, Hein Van Poppel b a Dokuz Eylul University School of Medicine, Department of Urology, Izmir, Turkey b Catholic University of Leuven UZ Gasthuisberg, Department of Urology, Leuven, Belgium Article info Article history: Accepted May 11, 2007 Published online ahead of print on May 24, 2007 Keywords: Kidney cancer Prognosis Renal cell carcinoma Staging survival Vascular invasion Venous thrombus Please visit europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically. Abstract Objective: Patients with kidney cancer with venous system involvement are at high risk of cancer recurrence even after the tumor thrombus is successfully removed. This review analyzes the impact on prognosis of the level of involvement of the inferior vena cava (IVC) in renal cell carcinoma (RCC). Methods: A literature search was done and relevant papers were reviewed. Relatively recent papers as well as large series or papers from expert centers are included in the reference list. Results: Venous invasion in RCC is a major challenge for urologists and patients with venous involvement have a worse prognosis. Although successful removal of a tumor thrombus in the renal vein and IVC may result in improved long-term survival in more than half of the affected patients, a higher level of thrombus appears to be a bad prognosticator for cancer recurrence. A complete IVC thrombectomy, even in the metastatic setting, provides a better quality of life and may prolong survival. Conclusions: Because surgery still remains the most effective therapeutic option in patients wtih RCC, every attempt should be made to completely remove the IVC thrombus. New targeted agents could be promising as adjuvant therapy in this subset of patients. # 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Corresponding author. Dokuz Eylul University School of Medicine, Department of Urology, Inciralti, Izmir 35340, Turkey. Tel ; Fax: address: ziya.kirkali@deu.edu.tr (Z. Kirkali). 1. Introduction Renal cell carcinoma (RCC) constitutes 3% of all solid neoplasms seen in humans and is an important health problem. There has been a worldwide increase in the incidence of RCC, partly attributed to earlier diagnosis following imaging for nonurologic problems. In parallel with the decrease in the size of incidentally detected kidney tumors, surgery for RCC is also changing from radical /$ see back matter # 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eururo

2 european urology 52 (2007) resection to more organ- and function-preserving approaches. Despite earlier diagnosis, up to 10% of patients with newly diagnosed RCC are still diagnosed with renal vein and inferior vena cava (IVC) involvement [1 4]. Because surgery remains the most effective form of treatment for RCC, every attempt is made to render the patient tumor free. This has prompted urologic surgeons to do radical nephrectomy even in the metastatic setting, including metastasectomy of resectable lesions and removal of the venous thrombus in the venous system. The surgical management of RCC with extension into the renal vein, IVC, or sometimes into the heart has always been a technically challenging and demanding operation for urologists. Developments in imaging, anesthesiology, and perioperative care now allow the safe removal of the thrombus, but there is still considerable morbidity and mortality in this type of surgery. A successful IVC thrombectomy provides considerable palliation to the patient and can sometimes lead to higher long-term survival rates. An aggressive surgical resection is proposed when there is IVC involvement because those patients who undergo only nephrectomy all die within 1 yr [5,6]. Patients with venous system involvement are still at high risk of cancer recurrence even after successful IVC thrombus removal. The correlation between the level of thrombus and the rate of survival has been extensively discussed in the literature. This review analyzes the level of involvement of the IVC and its impact on prognosis. 2. Level of thrombus IVC involvement is more common on the right than on the left side because of a shorter renal vein. Half of the IVC thrombi are infrahepatic and only 10% of them are located in the right atrium. Identifying the extent of IVC involvement is crucial for staging and surgical planning. Although the extent of an IVC thrombus can be identified by abdominal ultrasonography and computed tomography, the sensitivity of magnetic resonance imaging is superior to these techniques and is now the gold standard for assessing the level of IVC thrombus [7]. Inferior vena cavography is not often used. During surgery, transesophageal ultrasonography enables real-time visualization of the thrombus. A number of classification systems are used for the macroscopic vascular involvement in RCC. The Mayo classification is commonly used (Fig. 1) and consists of four categories based on the extension of Fig. 1 The Mayo classification of macroscopic venous invasion in renal cell carcinoma [8]. Level I: Tumor thrombus is either at the entry of the renal vein or within the inferior vena cava (IVC) < 2 cm from the confluence of the renal vein and the IVC. Level II: Thrombus extends within the IVC > 2 cm above the confluence of the renal vein and IVC but still remains below the hepatic veins. Level III: Thrombus involves the intrahepatic IVC. The size of the thrombus ranges from a narrow tail that extends into the IVC to one that fills the lumen and enlarges the IVC. Level IV: Thrombus extends above the diaphragm or into the right atrium. the thrombus [8]. Level I is when a thrombus is limited to the renal vein or <2 cm within the IVC. Level II is when the thrombus extends >2 cm within the IVC above the confluence of the renal vein and IVC but is still below the hepatic veins. Thrombus involving the intrahepatic IVC is level III. Level IV is when the thrombus extends above the diaphragm or into the right atrium. The surgical approach strategy is based on the proper assessment of the level of the venous extension. The most recent TNM classification only distinguishes between T3b tumors that grossly extend into the renal vein(s) or IVC or its wall below the diaphragm and T3c tumors that grossly extend into the IVC or its wall above the diaphragm [9].

3 660 european urology 52 (2007) Surgical treatment 4. Prognosis Surgery for IVC thrombus in RCC is a major operation and must be performed by experienced teams in experienced centers. Although most of the cases of minimal IVC extension can be dealt with through commonly used incisions, more extensive IVC thrombus may require different types of incisions and various types of surgical maneuvers such as hepatic mobilization, Pringle s maneuver, and venovenous bypass. Complex supradiaphragmatic and atrial tumor thrombi of RCC are still real challenges for the urologist. Many techniques have been described for the safe removal of these thrombi. Some authors advocate cardiopulmonary bypass with deep hypothermic arrest [10 12], but others advocate alternative techniques that avoid this type of approach, which can be highly morbid [3,5,13 15]. Vena cava resection may be required if the wall of the IVC is invaded by tumor. Recently, there have been an increasing number of reports of laparoscopic treatment of RCC with renal vein thrombosis [16]. Radical nephrectomy with removal of a thrombus from the IVC may be associated with major perioperative morbidity (up to 70%) and mortality (3 16%) [3,5,6,8,11,14,17]. The complication rates increase with the higher extension of the caval thrombus. The most common complication is significant blood loss. Reported transfusion amounts vary between 3 and 70 units [5,11]. The average blood loss is higher in patients with left-sided tumors and with higher levels of IVC thrombus. Table 1 Survival of patients with nonmetastatic renal cell carcinoma with venous thrombus Author/ reference Year No. Survival Skinner [5] yr OS 57% Galzer [12] yr OS 57% 5-yr CSS 60% Moinzadeh [20] yr OS Renal vein 66% IVC 29% Kim [19] yr CSS Renal vein 36% IVC 35% T3c 12% Lubahn [18] yr OS 56% Ciancio [15] yr PFS 53% Wagner [24] Median survival, mo Renal vein: 52 IVC below diaphragm: 25.8 IVC above diaphragm: 18 OS = overall survival; CSS = cancer-specific survival; IVC = inferior vena cava; PFS = progression-free survival. Although IVC thrombus implies a worse biologic behavior, it does not ultimately affect long-term prognosis [5,12,15,18 20]. Most of the patients with nonmetastatic RCC and renal vein or IVC tumor thrombus can have high progression-free, cancerspecific, and overall survival rates. Three questions have been extensively discussed in the literature concerning the impact of IVC thrombus removal on survival: (1) the impact of thrombus removal in nonmetastatic RCC and the adverse factors for survival; (2) the level of thrombus and its impact on survival; and (3) the impact of thrombus removal in metastatic RCC. These three issues will be discussed in turn The impact of thrombus removal in nonmetastatic RCC and the adverse factors for survival It is well known that even microscopic vascular invasion in a presumably localized RCC is a poor prognostic factor [21,22]. Thus, poor prognosis is also expected in patients with a macroscopic thrombus in the large vessels. Surgical removal of an IVC thrombus in a patients with nonmetastatic RCC should always be attempted to improve survival. Many authors have published series of tumor thrombus removal and the major series are summarized in Table 1. In some of the published reports, patients were diagnosed and treated a few decades ago when imaging, staging, and the quality of perioperative care were not as advanced as today. Even then, the overall survival at 5 yr seems to be >50%. It is evident that in a patient with venous thrombus, surgery with complete removal of the tumor has a major impact on survival. The adverse prognostic features for patients with venous thrombus are perinephric extension of RCC, lymph node metastasis, incomplete tumor or thrombus excision, and invasion of the IVC wall [1,2,5,8,23] The impact of the level of tumor thrombus on survival One of the most controversial topics in surgery for IVC thrombus in RCC has been the level of tumor thrombus and its impact on survival. The TNM staging of T3b and T3c is based on the assumption that a higher level of tumor thrombus is associated with a worse prognosis. Patients with more extensive thrombus propagation tend to have tumors of a higher grade and a more advanced local stage. Some reports showed lower rates of survival in patients with tumor thrombus in the IVC and in particular in those with higher cephalad extension

4 european urology 52 (2007) [5,15,19]. Skinner et al reviewed data on 56 patients and reported a 5-yr survival rate of 35% for level I, 18% for level II, and 0% for level III patients and concluded that thrombus level was an important prognosticator [5]. Kim et al studied 226 patients with venous thrombus and, after controlling for Fuhrman grade and performance status, they showed that patients with a tumor thrombus in the IVC above the diaphragm had a significantly worse survival rate than those with a renal vein or infradiaphragmatic IVC thrombus [19]. In a recent paper, Ciancio et al reported their experience of 56 patients, in which they found that 10 of 49 patients with level I III thrombus developed distant metastases during follow-up, whereas 4 of 7 patients with level IV thrombus developed metastases [15]. Other studies did not identify the level of IVC thrombus as a negative prognosticator [12,20].Glazer and Novick reviewed data on 18 patients with IVC thrombus extending into the right atrium and showed that their long-term survival was not significantly different from that of patients with infrahepatic or retrohepatic IVC thrombi [12]. The overall and cancer-specific 5-yr survival rates were 57% and 60%, respectively. Survival was better in patients without renal capsular extension compared to those with perinephric fat penetration (58.1 vs mo). It is suggested that prognosis is determined by pathologic stage or the IVC wall invasion rather than the level of extension [1]. Moinzadeh and Libertino, in a study of 153 patients, found that a higher level of thrombus was not associated with an increased spread of tumor in the perinephric fat or lymph nodes or with distant metastasis [20]. Fiveyear cancer-specific survival was similar in all levels of thrombus groups. However, 10-yr overall survival of patients with renal vein invasion only was 66%, whereas it was 29% for thrombus at the level of IVC. In a recent communication, a retrospective multicenter series of 1192 patients with pt3a and pt3b RCC who underwent nephrectomy was presented [24]. Having taken into account tumor size, perinephric fat invasion, lymph node involvement, distant metastases, and IVC thrombus, the authors concluded that IVC invasion at any level significantly and independently decreased the rate of survival The impact of thrombus removal in metastatic RCC How should the urologist approach patients with metastatic RCC and venous thrombus? These patients are usually symptomatic and have IVC syndrome, intractable edema, cardiac dysfunction, abdominal pain, or hematuria. Removal of the thrombus, even if it does not cure the patient, may relieve symptoms and provide a better quality of life. However, life expectancy, performance status, and comorbidity should all be taken into account. About a third of those patients with IVC thrombus have metastases. With the advent of new targeted therapies, survival of these patients might be improved with aggressive surgery and medical therapy. In a series of 30 patients an actuarial 5-yr survival rate of 17% was achieved where 80% of the patients were able to complete adjuvant immunotherapy [25]. Those patients with only lung metastases did much better. Zisman et al, reporting on a series of 207 patients with RCC and venous thrombus, found that whereas 63% of patients with tumor thrombus had metastases at diagnosis, only 25% of a cohort of 607 patients without thrombus had metastases [26]. The overall survival rate of patients with IVC thrombus was similar regardless of metastatic status, and metastatic patients with thrombus who underwent surgery had a significantly better response to immunotherapy than those treated nonoperatively. Thus, the combination of cytoreductive surgery and immunotherapy has an important role in the treatment of patients with renal vein thrombus and a potential role for those with IVC thrombus. 5. Conclusions Venous invasion in RCC is major surgery for urologists and patients with venous involvement have worse prognostic indicators. Successful removal of the tumor thrombus in the renal vein and IVC may result in improved long-term survival rates for more than half of the affected patients. The higher the level of thrombus the higher the likelihood of cancer recurrence. Removal of the IVC thrombus, even in the metastatic setting, provides a better quality of life and may prolong survival. Because surgery is still the most effective therapeutic option in patients with RCC, every attempt must be made to completely remove the IVC thrombus. New targeted agents may be promising as adjuvant therapy in this subset of patients. Conflicts of interest The authors have nothing to disclose. References [1] Hatcher PA, Anderson EE, Paulson DF, et al. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol 1991;145:20 4.

5 662 european urology 52 (2007) [2] Hoehn W, Hermanek P. Invasion of veins in renal cell carcinoma frequency, correlation, and prognosis. Eur Urol 1983;9: [3] Nesbitt JC, Soltero ER, Dinney CPN, et al. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Ann Thorac Surg 1997;63: [4] Pagano F, Dal Bianco M, Artibani W, et al. Renal cell carcinoma with extension into the inferior vena cava: problems in diagnosis, staging, and treatment. Eur Urol 1992;22: [5] Skinner DG, Pritchett TR, Lieskovsky G, et al. Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. Ann Surg 1989;210: [6] Sosa RE, Muecke EC, Vaughan Jr ED, et al. Renal carcinoma extending into the inferior vena cava: the prognostic significance of the level of vena caval involvement. J Urol 1984;132: [7] Kallman DA, King BF, Hattery RR, et al. Renal vein and inferior vena tumor thrombus in renal cell carcinoma: CT, US, MRI, and vena cavography. J Comput Assist Tomogr 1992;16: [8] Neves RJ, Zincke H. Surgical treatment of renal cancer with vena cava extension. Br J Urol 1987;59: [9] Sobin LH, Wittekind CH, editors. UICC International Union Against Cancer. TNM classification of malignant tumors. ed. 6. New York: Wiley-Liss; p [10] Montie JE, Jackson CL, Cosgrove DM, et al. Resection of large inferior vena caval thrombi from renal cell carcinoma with the use of circulatory arrest. J Urol 1988;139: [11] Novick AC, Kaye MC, Cosgrove DM, et al. Experience with cardiopulmonary bypass and hypothermic arrest in the management of retroperitoneal tumors with large vena cava thrombi. Ann Surg 1990;212: [12] Glazer AA, Novick AC. Long-term follow-up after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol 1996;155: [13] Ciancio G, Hawke C, Soloway M. The use of liver transplant techniques to aid in the surgical management of urological tumors. J Urol 2000;164: [14] Langenburg SE, Blackbourne LH, Sperling JW, et al. Management of renal tumors involving the inferior vena cava. J Vasc Surg 1994;20: [15] Ciancio G, Livingstone AS, Soloway M. Surgical management of renal cell carcinoma with tumor thrombus in the renal and inferior vena cava: the University of Miami experience in using liver transplantation techniques. Eur Urol 2007;51: [16] Desai MM, Gill IS, Ramani AP, et al. Laparoscopic radical nephrectomy for cancer with level I renal vein involvement. J Urol 2003;169: [17] Libertino JA, Zinman L, Watkins Jr E. Long term results of resection of renal cell cancer with extension into inferior vena cava. J Urol 1987;137:21 4. [18] Lubahn JG, Sagalowsky AI, Rosenbaum DH, et al. Contemporary techniques and safety of cardiovascular procedures in the surgical management of renal cell carcinoma with tumor thrombus. J Thora Cardiovasc Surg 2006;131: [19] Kim HL, Zisman A, Han K, et al. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol 2004;171: [20] Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol 2004;171: [21] Sevinc M, Kirkali Z, Yorukoglu K, Mungan U, Sade M. Prognostic significance of microvascular invasion in localized renal cell carcinoma. Eur Urol 2000;38: [22] Van Poppel H, Vandendriessche H, Boel K, et al. Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. J Urol 1997;158:45 9. [23] Heney NM, Nocks BN. The influence of perinephric fat involvement on survival in patients with renal cell carcinoma extending into the vena cava. J Urol 1982;128: [24] Wagner B, Patard JJ, Méjean A, et al. Prognostic value of renal vein (RV) and inferior vena cava (IVC) involvement in renal cell carcinoma (RCC). Eur Urol Suppl 2007;6:159 (abstract no. 546). [25] Naitoh J, Kaplan A, Dorey F, et al. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. J Urol 1999;162: [26] Zisman A, Wieder JA, Pantuck AJ, et al. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to imunotherapy. J Urol 2003;169:

Kidney Cancer OVERVIEW

Kidney Cancer OVERVIEW Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney

More information

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies

More information

Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma

Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma 窑 Original Article 窑 Chinese Journal of Cancer Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma Zhi Ling Zhang,2, Yong Hong Li,2, Yong Hong Xiong 3, Guo Liang Hou,2,

More information

A912: Kidney, Renal cell carcinoma

A912: Kidney, Renal cell carcinoma A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type

More information

The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006

The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy

More information

The TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK

The TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.

More information

Guidelines for Management of Renal Cancer

Guidelines for Management of Renal Cancer Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated

More information

Renal cell cancer: pathologic and prognostic factors and new staging strategies

Renal cell cancer: pathologic and prognostic factors and new staging strategies ORIGINAL ARTICLE Renal cell cancer: pathologic and prognostic factors and new staging strategies Zael Santana-Ríos, Alejandro Urdiales-Ortíz, Héctor Camarena-Reynoso, Santiago Fulda-Graue, Rodrigo Pérez-Becerra,

More information

Resection of Renal Tumors Invading thevena Cava

Resection of Renal Tumors Invading thevena Cava Resection of Renal Tumors Invading thevena Cava Chad Wotkowicz, MD*, Matthew F.Wszolek, MD, John A. Libertino, MD KEYWORDS Renal cell carcinoma Inferior vena cava Surgical management Renal cell carcinoma

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD

SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:

More information

Significant Heterogeneity in terms of Diagnosis and Treatment of Renal Cell Carcinoma at a Private and Public Hospital in Brazil

Significant Heterogeneity in terms of Diagnosis and Treatment of Renal Cell Carcinoma at a Private and Public Hospital in Brazil Clinical Urology Heterogeneity to renal cell carcinoma International Braz J Urol Vol. 37 (5): 584-590, September - October, 2011 Significant Heterogeneity in terms of Diagnosis and Treatment of Renal Cell

More information

Smoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.

Smoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer. Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which

More information

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma. Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of

More information

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center

More information

Diagnosis and Prognosis of Pancreatic Cancer

Diagnosis and Prognosis of Pancreatic Cancer Main Page Risk Factors Reducing Your Risk Screening Symptoms Diagnosis Treatment Overview Chemotherapy Radiation Therapy Surgical Procedures Lifestyle Changes Managing Side Effects Talking to Your Doctor

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microwave_tumor_ablation 12/2011 11/2015 11/2016 11/2015 Description of Procedure or Service Microwave ablation

More information

Renal Cell Carcinoma: Prognostic Factors and Patient Selection

Renal Cell Carcinoma: Prognostic Factors and Patient Selection european urology supplements 6 (2007) 477 483 available at www.sciencedirect.com journal homepage: www.europeanurology.com Renal Cell Carcinoma: Prognostic Factors and Patient Selection Arie S. Belldegrun

More information

Translocation Renal Cell Carcinomas

Translocation Renal Cell Carcinomas Translocation Renal Cell Carcinomas Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Kidney cancer is not a single disease Clear cell (75%)

More information

Medullary Renal Cell Carcinoma Case Report

Medullary Renal Cell Carcinoma Case Report Bahrain Medical Bulletin, Vol. 27, No. 4, December 2005 Medullary Renal Cell Carcinoma Case Report Mohammed Abdulla Al-Tantawi MBBCH, CABS* Abdul Amir Issa MBBCH, CABS*** Mohammed Abdulla MBBCH, CABS**

More information

Management of Locally Advanced Renal Cell Carcinoma

Management of Locally Advanced Renal Cell Carcinoma The prognostic factors, potential biomarkers, surgical strategies, and adjuvant therapy trials for patients with locally advanced renal cell carcinoma are reviewed. Kala Pohl. Let s Stick Together. Acrylic

More information

BJUI. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus REVIEW ARTICLE

BJUI. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus REVIEW ARTICLE BJUI REVIEW ARTICLE Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus Samuel M. Lawindy, Tony Kurian, Timothy Kim, Devanand

More information

Tumour nephrectomy with vena cava thrombus

Tumour nephrectomy with vena cava thrombus Original Article surgery illustrated BACHMANN et al. Tumour nephrectomy with vena cava thrombus ALEXANDER BACHMANN, MICHAEL SEITZ, ANNO GRASER*, MAXIMILIAN F. REISER*, HANS-JOACHIM SCHÄFERS, FLORIAN LÖHE,

More information

Metastatic renal cell carcinoma to the left maxillary sinus

Metastatic renal cell carcinoma to the left maxillary sinus Case Report Metastatic renal cell carcinoma to the left maxillary sinus Y.-F. He 1, J. Chen 1, W.-Q. Xu 2, C.-S. Ji 1, J.-P. Du 1, H.-Q. Luo 1 and B. Hu 1 1 Department of Medical Oncology, The Provincial

More information

Current Status and Perspectives of Radiation Therapy for Breast Cancer

Current Status and Perspectives of Radiation Therapy for Breast Cancer Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic

More information

CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA

CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA Stephen A. Boorjian, MD Professor of Urology Vice Chair of Research Director, Urologic Oncology Fellowship Department of Urology Mayo Clinic, Rochester,

More information

Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment

Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information

More information

Transperitoneal laparoscopic adrenalectomy for metachronous contralateral

Transperitoneal laparoscopic adrenalectomy for metachronous contralateral Transperitoneal laparoscopic adrenalectomy for metachronous contralateral adrenal metastasis from renal cell carcinoma: a case report Evangelos Zacharakis* 1, Maria Jose Ribal 1, Emmanouil Zacharakis 2

More information

LIVER CANCER AND TUMOURS

LIVER CANCER AND TUMOURS LIVER CANCER AND TUMOURS LIVER CANCER AND TUMOURS Healthy Liver Cirrhotic Liver Tumour What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood

More information

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,

More information

Renal cell carcinoma in India demonstrates early age of onset & a late stage of presentation

Renal cell carcinoma in India demonstrates early age of onset & a late stage of presentation Indian J Med Res 140, November 2014, pp 624-629 Renal cell carcinoma in India demonstrates early age of onset & a late stage of presentation Shalini Agnihotri, Jatinder Kumar, Manoj Jain *, Rakesh Kapoor

More information

Evidence tabel Lokaal palliatieve behandelingen

Evidence tabel Lokaal palliatieve behandelingen Auteurs, jaartal Mate van bewijs Studie type Follow-up Populatie (incl. steekproef-grootte) Patienten kenmerken Interventie Controle Resultaten Conclusie Opmerkingen, commentaar Hartgrink, 2002 The Netherlands

More information

OBJECTIVES By the end of this segment, the community participant will be able to:

OBJECTIVES By the end of this segment, the community participant will be able to: Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway

More information

Pattern of metastases in renal cell carcinoma: a single institution study

Pattern of metastases in renal cell carcinoma: a single institution study Original Article Pattern of metastases in renal cell carcinoma: a single institution study Sivaramakrishna B, Gupta Narmada P, Wadhwa P, Hemal Ashok K, Dogra Prem N, Seth A, Aron M, Kumar R Department

More information

Image. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.

Image. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors. Neoplasms of the Ear and Lateral Skull Base Image 3.11.1 SW What are the three most common neoplasms of the auricle? 3.11.2 SW What are the four most common neoplasms of the external auditory canal (EAC)

More information

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500

More information

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,

More information

Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy

Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy Derya Tilki,*, Brian Hu, Hao G. Nguyen, Marc A. Dall

More information

Neoadjuvant and Adjuvant Hormone Therapy: How and When?

Neoadjuvant and Adjuvant Hormone Therapy: How and When? european urology supplements 7 (2008) 747 751 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neoadjuvant and Adjuvant Hormone Therapy: How and When? Hein Van Poppel * Department

More information

Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer

Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program Staging Most important in risk assessment and

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

SARCOMATOID DIFFERENTIATION IN RENAL CELL CARCINOMA: PROGNOSTIC IMPLICATIONS

SARCOMATOID DIFFERENTIATION IN RENAL CELL CARCINOMA: PROGNOSTIC IMPLICATIONS Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology SARCOMATOID DIFFERENTIATION IN RCC Vol. 31 (1): 101, January February, 2005 SARCOMATOID DIFFERENTIATION IN

More information

Introduction. Case History

Introduction. Case History NAOSITE: Nagasaki University's Ac Title Author(s) A Case Report of Renal Cell Carcino Shimajiri, Shouhei; Shingaki, Yoshi Masaya; Tamamoto, Tooru; Toda, Taka Citation Acta Medica Nagasakiensia. 1992, 37

More information

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths

More information

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the

More information

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of

More information

Metastatic Breast Cancer...

Metastatic Breast Cancer... DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a

More information

Surgical Management of Kidney Cancer. Adam R. Metwalli, M.D. Urologic Oncology Branch National Cancer Institute

Surgical Management of Kidney Cancer. Adam R. Metwalli, M.D. Urologic Oncology Branch National Cancer Institute Surgical Management of Kidney Cancer Adam R. Metwalli, M.D. Urologic Oncology Branch National Cancer Institute Background Cancer of the Kidney 95% of cases refers to Renal Cell Carcinoma (RCC) 5% refers

More information

Your Guide to Express Critical Illness Insurance Definitions

Your Guide to Express Critical Illness Insurance Definitions Your Guide to Express Critical Illness Insurance Definitions Your Guide to EXPRESS Critical Illness Insurance Definitions This guide to critical illness definitions will help you understand the illnesses

More information

RENAL CELL CARCINOMA WITH RETROPERITONEAL LYMPH NODES: ROLE OF LYMPH NODE DISSECTION

RENAL CELL CARCINOMA WITH RETROPERITONEAL LYMPH NODES: ROLE OF LYMPH NODE DISSECTION 0022-5347/03/1696-2076/0 Vol. 169, 2076 2083, June 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000066130.27119.1c RENAL CELL CARCINOMA

More information

The Royal Marsden. Surgery for Gastric and GE Junction Cancer: primary palliative where and when? William Allum

The Royal Marsden. Surgery for Gastric and GE Junction Cancer: primary palliative where and when? William Allum The Royal Marsden Surgery for Gastric and GE Junction Cancer: primary palliative where and when? William Allum Any surgeon can cure Surgeon - dependent No surgeon can cure EMR D2 GASTRECTOMY H N SN. WEDGE

More information

Metastatic Prostate Cancer Causing Complete Obstruction of the IVC

Metastatic Prostate Cancer Causing Complete Obstruction of the IVC Department of Radiology Henry Ford Health System Detroit, Michigan Metastatic Prostate Cancer Causing Complete Obstruction of the IVC Jennifer Johnston MSIII, Wayne State Medical School Stage 4 Metastatic

More information

Current and Future Trends in the Treatment of Renal Cancer

Current and Future Trends in the Treatment of Renal Cancer european urology supplements 6 (2007) 374 384 available at www.sciencedirect.com journal homepage: www.europeanurology.com Current and Future Trends in the Treatment of Renal Cancer Thomas Keane a, *,

More information

Lung cancer is not just one disease. There are two main types of lung cancer:

Lung cancer is not just one disease. There are two main types of lung cancer: 1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available

More information

Clinical Indications and Results Following Chest Wall Resection

Clinical Indications and Results Following Chest Wall Resection Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division

More information

Prognostic factors in locally advanced prostate cancer as determined by biochemistry, imaging studies and pathology

Prognostic factors in locally advanced prostate cancer as determined by biochemistry, imaging studies and pathology Prognostic factors in locally advanced prostate cancer as determined by biochemistry, imaging studies and pathology Authors Key words C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel Prognostic

More information

9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH

9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH 9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing

More information

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012 Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos

More information

Hepatocellular Carcinoma: What the hepatologist wants to know

Hepatocellular Carcinoma: What the hepatologist wants to know Hepatocellular Carcinoma: What the hepatologist wants to know Hélène Castel, MD Liver Unit Hôpital St-Luc CHUM? CAR Annual Scientific Meeting Saturday, April 27 th 2013 Disclosure statement I do not have

More information

How To Treat Lung Cancer At Cleveland Clinic

How To Treat Lung Cancer At Cleveland Clinic Treatment Guide Lung Cancer Management The Chest Cancer Center at Cleveland Clinic, which includes specialists from the Respiratory Institute, Taussig Cancer Institute and Miller Family Heart & Vascular

More information

THYROID CANCER. I. Introduction

THYROID CANCER. I. Introduction THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in

More information

GUIDELINES ON RENAL CELL CARCINOMA

GUIDELINES ON RENAL CELL CARCINOMA GUIDELINES ON RENAL CELL CARCINOMA (Text update March 2015) B. Ljungberg (Chair), K. Bensalah, A. Bex (Vice-chair), S. Canfield, S. Dabestani (Guidelines Associate), R. Giles (Patient Organisation Representative),

More information

PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY. Dr. Shailesh V. Shrikhande

PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY. Dr. Shailesh V. Shrikhande PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY Dr. Shailesh V. Shrikhande Associate Professor & Consultant Surgeon GI and HPB Surgical Oncology Tata Memorial Hospital, Mumbai INDIA HELICAL

More information

Treatment of mesothelioma in Bloemfontein, South Africa

Treatment of mesothelioma in Bloemfontein, South Africa European Journal of Cardio-thoracic Surgery 24 (2003) 434 440 www.elsevier.com/locate/ejcts Treatment of mesothelioma in Bloemfontein, South Africa W.J. de Vries*, M.A. Long Cardiothoracic Department,

More information

Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014

Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014 Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014 Prof. Dr. Chris Verslype, Leuven Prof. Dr. Aurel Perren, Bern Menue Challenges: 1. Gastric NET 2. Appendiceal NET 3. Rectal NET SEER,

More information

Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科

Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)

More information

Surgical Staging of Endometrial Cancer

Surgical Staging of Endometrial Cancer Surgical Staging of Endometrial Cancer I. Endometrial Cancer Surgical Staging Overview Uterine cancer types: carcinomas type I and type II, sarcomas, carcinosarcomas Hysterectomy with BSO Surgical Staging

More information

RCC accounts for 3% of all malignant tumors and now

RCC accounts for 3% of all malignant tumors and now Prognostic Value of Thrombocytosis in Renal Cell Carcinoma Karim Bensalah, Emmanuelle Leray, Patricia Fergelot, Nathalie Rioux-Leclercq, Jacques Tostain, François Guillé and Jean-Jacques Patard* From the

More information

Update on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery

Update on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David

More information

UICC World Cancer Congress. Cancer Staging and Quality of Care

UICC World Cancer Congress. Cancer Staging and Quality of Care UICC World Cancer Congress August 27 30, 2012, Montreal CANCER STAGE: A neglected cornerstone of Cancer Control Cancer Staging and Quality of Care Christian Wittekind Institut für Pathologie UKL 1 Agenda!

More information

Frequently Asked Questions About Ovarian Cancer

Frequently Asked Questions About Ovarian Cancer Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues

More information

Does my patient need more therapy after prostate cancer surgery?

Does my patient need more therapy after prostate cancer surgery? Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier

More information

PET/CT in Lung Cancer

PET/CT in Lung Cancer PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT

More information

Thyroid and Adrenal Gland

Thyroid and Adrenal Gland Thyroid and Adrenal Gland NAACCR 2011 2012 Webinar Series 12/1/11 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar

More information

Kidney Cancer. Understanding your diagnosis

Kidney Cancer. Understanding your diagnosis Kidney Cancer Understanding your diagnosis Kidney Cancer Understanding your diagnosis When you first hear that you have cancer, you may feel alone and afraid. You may be overwhelmed by the large amount

More information

Cancer of the Cervix

Cancer of the Cervix Cancer of the Cervix WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 A woman's cervix (the opening of the uterus) is lined with cells. Cancer of the cervix occurs when those cells change,

More information

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited

More information

Clinical Practice Assessment Robotic surgery

Clinical Practice Assessment Robotic surgery Clinical Practice Assessment Robotic surgery Background: Surgery is by nature invasive. Efforts have been made over time to reduce complications and the trauma inherently associated with surgery through

More information

Sternotomy and removal of the tumor

Sternotomy and removal of the tumor Sternotomy and removal of the tumor All thymomas originate from epithelial thymic cells 4% of them consist of a pure population of epithelial cells Most have mixed populations of lymphoid cells to a

More information

Case Number: RT2009-124(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor

Case Number: RT2009-124(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor Renal Cell Carcinoma of the Left Kidney Post Radical Surgery with pt4 Classification with Multiple Lung and Single Brain Metastases: the Role and Treatment Consideration of Radiotherapy Case Number: RT2009-124(M)

More information

ECG may be indicated for patients with cardiovascular risk factors

ECG may be indicated for patients with cardiovascular risk factors eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,

More information

How to treat early gastric cancer. Surgery

How to treat early gastric cancer. Surgery How to treat early gastric cancer Surgery Mark I. van Berge Henegouwen Department of Surgery, AMC, Amsterdam Director upper GI surgical unit Academic Medical Center Upper GI surgery at AMC 100 oesophagectomies

More information

Prostate Cancer What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer?

Prostate Cancer What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer? Prostate Cancer What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer? Stacy Loeb, Edward M. Schaeffer, Bruce J. Trock, Jonathan I. Epstein, Elizabeth B. Humphreys, and Patrick C.

More information

The lungs What is lung cancer? How common is it? Risks & symptoms Diagnosis & treatment options

The lungs What is lung cancer? How common is it? Risks & symptoms Diagnosis & treatment options Why We re Here The lungs What is lung cancer? How common is it? Risks & symptoms Diagnosis & treatment options What Are Lungs? What Do They Do? 1 Located in the chest Allow you to breathe Provide oxygen

More information

RENAL CANCER PATHOLOGY WHAT REALLY MATTERS? STEWART FLEMING UNIVERSITY OF DUNDEE

RENAL CANCER PATHOLOGY WHAT REALLY MATTERS? STEWART FLEMING UNIVERSITY OF DUNDEE RENAL CANCER PATHOLOGY WHAT REALLY MATTERS? STEWART FLEMING UNIVERSITY OF DUNDEE MAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER Molecular differential pathology of renal cell tumours

More information

Radiotherapy in locally advanced & metastatic NSC lung cancer

Radiotherapy in locally advanced & metastatic NSC lung cancer Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced

More information

Patterns of nodal spread in thoracic malignancies

Patterns of nodal spread in thoracic malignancies Patterns of nodal spread in thoracic malignancies Poster No.: C-0977 Congress: ECR 2010 Type: Educational Exhibit Topic: Chest Authors: R. dos Santos, M. Duarte, J. Alpendre, J. Castaño, Z. Seabra, Â.

More information

Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence

Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence Post- survival in completely resected stage I non-small cell lung cancer with local J-J Hung, 1,2,3 W-H Hsu, 3 C-C Hsieh, 3 B-S Huang, 3 M-H Huang, 3 J-S Liu, 2 Y-C Wu 3 See Editorial, p 185 c A supplementary

More information

We carried out excision of a solitary bony

We carried out excision of a solitary bony Radical surgery for the solitary bony metastasis from renal-cell carcinoma K. G. Baloch, R. J. Grimer, S. R. Carter, R. M. Tillman From the Royal Orthopaedic Hospital Oncology Service, Birmingham, England

More information

Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy

Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy Sarah Hutto,, MSIV Marc Underhill, M.D. January 27, 2009 Past History 45 yo female

More information

Ching-Yao Yang, Yu-Wen Tien

Ching-Yao Yang, Yu-Wen Tien Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at

More information

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40. A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate

More information

da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy)

da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy) da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy) Prostate Cancer Overview Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the

More information

Mesothelioma. 1995-2013, The Patient Education Institute, Inc. www.x-plain.com ocft0101 Last reviewed: 03/21/2013 1

Mesothelioma. 1995-2013, The Patient Education Institute, Inc. www.x-plain.com ocft0101 Last reviewed: 03/21/2013 1 Mesothelioma Introduction Mesothelioma is a type of cancer. It starts in the tissue that lines your lungs, stomach, heart, and other organs. This tissue is called mesothelium. Most people who get this

More information

Something Old, Something New.

Something Old, Something New. Something Old, Something New. Michelle A. Fajardo, D.O. Loma Linda University Medical Center Clinical Presentation 6 year old boy, presented with hematuria Renal mass demonstrated by ultrasound & CT scan

More information

Understanding Metastatic Disease

Understanding Metastatic Disease Supported by an unrestricted educational grant from Pfizer Understanding Metastatic Disease Metastatic disease or metastases are phrases that mean the same as Secondary cancer. This means that the cancer

More information

Survival analysis of 220 patients with completely resected stage II non small cell lung cancer

Survival analysis of 220 patients with completely resected stage II non small cell lung cancer 窑 Original Article 窑 Chinese Journal of Cancer Survival analysis of 22 patients with completely resected stage II non small cell lung cancer Yun Dai,2,3, Xiao Dong Su,2,3, Hao Long,2,3, Peng Lin,2,3, Jian

More information